Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference74 articles.
1. Unlocking the potential of antibody-drug conjugates for cancer therapy;Nat Rev Clin Oncol,2021
2. Trastuzumab emtansine for HER2-positive advanced breast cancer;N Engl J Med,2012
3. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer;N Engl J Med,2022
4. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer;N Engl J Med,2022
5. Strategies and challenges for the next generation of antibody-drug conjugates;Nat Rev Drug Discov,2017
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer;Cancer;2024-01-25
2. Exploring the Sensitivity of Antibody–Drug Conjugate Efficacy to the Selection of Payload, Antibody, and Cell line;Bioconjugate Chemistry;2024-01-04
3. Managing adverse events of sacituzumab govitecan;Expert Opinion on Biological Therapy;2023-10-09
4. Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer;Expert Opinion on Pharmacotherapy;2023-04-11
5. Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype;Pharmaceutics;2023-03-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3